Please login to the form below

Not currently logged in
Email:
Password:

Biotie

This page shows the latest Biotie news and features for those working in and with pharma, biotech and healthcare.

Acorda acquires Biotie to expand in Parkinson's disease

Acorda acquires Biotie to expand in Parkinson's disease

Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... Biotie also has a royalty stream from Lundbeck's sales of

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    410. Biotie Oy/ Acorda. Acquisition company. CNS portfolio includes tozadenant for Parkinson's in p2b .

  • Pharma deals during September 2012 Pharma deals during September 2012

    Lundbeck has subscribed for 4.6 per cent of Biotie Therapeutics shares for 10m (25 per cent premium to the subscription price). The companies already have a worldwide exclusive licence agreement ... term cash injection, as in August, Biotie had

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics